These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35525830)

  • 1. The Effect of Biosimilar Prescription Targets for Erythropoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany.
    Birkner B; Blankart KE
    Value Health; 2022 Sep; 25(9):1528-1538. PubMed ID: 35525830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany.
    Blankart KE; Arndt F
    Int J Environ Res Public Health; 2020 Jun; 17(11):. PubMed ID: 32526943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
    Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
    Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
    Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Tari DU; Troncone C; Fontana A; Ientile V; Gini R; Santoro D; Santarpia M; Genazzani A; Uomo I; Pastorello M; Addario WS; Scondotto S; Cananzi P; Caputi AP; Trifirò G
    BioDrugs; 2015 Aug; 29(4):275-84. PubMed ID: 26169209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.
    Beck M; Michel B; Rybarczyk-Vigouret MC; Levêque D; Sordet C; Sibilia J; Velten M;
    BioDrugs; 2016 Dec; 30(6):585-592. PubMed ID: 27848166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
    Dean EB; Johnson P; Bond AM
    JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
    Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
    Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review.
    Leonard E; Wascovich M; Oskouei S; Gurz P; Carpenter D
    J Manag Care Spec Pharm; 2019 Jan; 25(1):102-112. PubMed ID: 30589628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
    Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative.
    Edgar BS; Cheifetz AS; Helfgott SM; Smith GP; Bandekar T; Hoye-Simek A; Liu Y; Singh RM; Fajardo KI; Carter J; Simone L
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1129-1135. PubMed ID: 34337986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of an intervention strategy in the biosimilar glargine prescription pattern in primary care].
    Saborido-Cansino C; Santos-Ramos B; Carmona-Saucedo C; Rodríguez-Romero MV; González-Martín A; Palma-Amaro A; Rojas-Lucena IM; Almeida-González C; Sánchez-Fidalgo S
    Aten Primaria; 2019; 51(6):350-358. PubMed ID: 29861115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
    Bokemeyer B; Dignaß A; Schreiber S
    Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biosimilars and the efficiency principle].
    Münnch T
    Laryngorhinootologie; 2017 Dec; 96(12):828-830. PubMed ID: 29195262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.
    Moorkens E; Barcina Lacosta T; Vulto AG; Schulz M; Gradl G; Enners S; Selke G; Huys I; Simoens S
    Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33096709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
    Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
    BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Turk F; Huys I
    BMC Health Serv Res; 2022 Sep; 22(1):1211. PubMed ID: 36175885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Observational Study of Retail Pharmacy Naloxone Prescriptions: Differences Across Provider Specialties and Patient Populations.
    Smart R; Geiger CK; Jones CM; Stein BD
    J Gen Intern Med; 2020 Jun; 35(6):1768-1775. PubMed ID: 31637652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Robinson BM; Locatelli F; Pisoni RL
    Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.